Menu
  • Join
  • Login
  • Contact
 

Search abstracts


A new anti-tumor inhibitor targeting PLK1 PBD

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: ZHANG, Jing (Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences, Beijing, China)
  • Co-author(s): Jing Zhang: Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences, Beijing, China
    Yunyu Chen: Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences, Beijing, China
    Shuyi Si: Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences, Beijing, China
  • Abstract:

    Backgrounds

    PLKs contain an N-terminal serine/threonine kinase domain and a C-terminal Polo-box region. Due to the conserved nature of the ATP-binding pocket, the drugs that target the kinase domain might not be specific to PLK1. As PBD is unique and a specific signature of the PLK kinase family, targeting the PBD of PLK1 has been postulated as an..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses